Scots say yes to BMS/Pfizer's Eliquis and BI's Trajenta
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium, has given the green light to Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for stroke prevention and Boehringer Ingelheim's Trajenta (linagliptin) for improving glyecamic control in type 2 diabetes patients.